

(19) **DANMARK**

(10) **DK/EP 2630118 T3**



(12) **Oversættelse af
europæisk patentskrift**

Patent- og
Varemærkestyrelsen


-
- (51) Int.Cl.: **C 07 C 247/12 (2006.01)** **C 07 C 209/42 (2006.01)** **C 07 C 233/48 (2006.01)**
C 07 C 253/30 (2006.01) **C 07 C 255/29 (2006.01)**
- (45) Oversættelsen bekendtgjort den: **2015-02-09**
- (80) Dato for Den Europæiske Patentmyndigheds bekendtgørelse om meddelelse af patentet: **2014-11-05**
- (86) Europæisk ansøgning nr.: **11811559.1**
- (86) Europæisk indleveringsdag: **2011-10-19**
- (87) Den europæiske ansøgnings publiceringsdag: **2013-08-28**
- (86) International ansøgning nr.: **IB2011002507**
- (87) Internationalt publikationsnr.: **WO2012052829**
- (30) Prioritet: **2010-10-19 IN CH20103087** **2011-07-13 IN CH23952011**
- (84) Designerede stater: **AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR**
- (73) Patenthaver: **MYLAN LABORATORIES LIMITED, Plot No. 564/A/22, Road No. 92 , Jubilee Hills , Hyderabad, 500033 Andhra Pradesh, Indien**
- (72) Opfinder: **RAMA, Shankar, PLOT NO 564/A/22, ROAD NO 92, JUBILEE HILLS, HYDERABAD - 500033, Indien**
VADALI, Lakshmana Rao, PLOT NO 564/A/22, ROAD NO 92, JUBILEE HILLS, HYDERABAD - 500033, Indien
PALLA, Vijay Kumar, PLOT NO 564/A/22, ROAD NO 92, JUBILEE HILLS, HYDERABAD - 500033, Indien
SAIDUGARI, Swamy, PLOT NO 564/A/22, ROAD NO 92, JUBILEE HILLS, HYDERABAD - 500033, Indien
MITTAPELLY, Nagaraju, PLOT NO 564/A/22, ROAD NO 92, JUBILEE HILLS, HYDERABAD - 500033, Indien
JALDU, Ravikanth, PLOT NO 564/A/22, ROAD NO 92, JUBILEE HILLS, HYDERABAD - 500033, Indien
VIJAYA, Krishna Ravi, PLOTNO 564/A/22, ROAD NO 92, JUBILEE HILLS, HYDERABAD - 500033, Indien
SESHADRI, Rao Manukonda, PLOT NO 564/A/22, ROAD NO 92, JUBILEE HILLS, HYDERABAD - 500033, Indien
DASARL, Srinivasa Rao, PLOT NO 564/A/22, ROAD NO 92, JUBILEE HILLS, HYDERABAD - 500033, Indien
SRINIVASA, Rao Potla, PLOT NO 564/A/22, ROAD NO 92, JUBILEE HILLS, HYDERABAD - 500033, Indien
DANDALA, Ramesh, PLOT NO 564/A/22, ROAD NO 92, JUBILEE HILLS, HYDERABAD - 500033, Indien
- (74) Fuldmægtig i Danmark: **NORDIC PATENT SERVICE A/S, Højbro Plads 10, 1200 København K, Danmark**
- (54) Benævnelse: **SYNTESE AF ALISKIREN**
- (56) Fremdragne publikationer:
WO-A1-2011/148392
US-A1- 2003 149 303
SANDHAM D A ET AL: "A convergent synthesis of the renin inhibitor CGP60536B", TETRAHEDRON LETTERS, ELSEVIER, AMSTERDAM, NL, vol. 41, no. 51, 16 December 2000 (2000-12-16), pages 10091-10094, XP004225223, ISSN: 0040-4039, DOI: 10.1016/S0040-4039(00)01760-3

Description

[0001] The present invention relates to novel process for the preparation of renin inhibitor Aliskiren or its derivatives, and its pharmaceutically acceptable salts.

BACKGROUND OF THE INVENTION

- 5 [0002] Aliskiren, (2S, 4S, 5S, 7S)-N-(2-carbamoyl-2-methylpropyl)-5-amino-4-hydroxy-2,7-diisopropyl-8-[4-methoxy-3-(3-methoxypropoxy)phenyl] octanamide having the Formula-I, a new antihypertensive has been developed which interferes with the renin-angiotensin system at the beginning of angiotensin II biosynthesis.



Formula-I

- 10 [0003] Aliskiren is marketed by Novartis as TEKTURNA® in the form of its hemifumarate salt in a once-daily formulation. More recently Aliskiren is also formulated as combination with other API.

[0004] U.S. pat. No. 5,559,111 discloses Aliskiren and related compounds along with the different approaches for the synthesis of Aliskiren.

15

[0005] Further US 7132569, US 7009078, US 6730798 and US 6800769 claims novel intermediates used in the preparation of Aliskiren and process for the preparation of Aliskiren, which are incorporated here for reference.

- 20 [0006] As the compound comprises, 4 chiral carbon atoms, the synthesis of the enantiomerically pure compound is quite demanding. Therefore, novel routes of synthesis needed for the preparation of Aliskiren.

- [0007] The present invention provides novel intermediates used in the preparation of Aliskiren and
25 process for the preparation of Aliskiren.


OBJECT AND SUMMARY OF THE INVENTION

[0008] Principle object of the present invention is to provide a novel process for the preparation of Aliskiren, (2S,4S,5S,7S)-N-(2-carbamoyl-2-methylpropyl)-5-amino-4-hydroxy-2,7-diisopropyl-8-[4-methoxy-3-(3-methoxypropoxy)phenyl] octanamide or its pharmaceutically acceptable salts.

[0009] Another object of the present invention is to provide novel intermediate of compound of Formula-III used in the preparation of Aliskiren.


[0010] In one aspect the present invention provides, novel process for the preparation of renin inhibitor of compound of Formula-Ia comprising the steps of:

a) reacting compound of Formula-II, with a cyano compound 3-Amino-2,2-dimethyl-propionitrile




Formula-II

wherein R₁ and R₂ are independently of one another H, C₁-C₆alkyl, C₁-C₆ halogen alkyl, C₁-C₆alkoxy, C₁-C₆alkoxy-C₁-C₆alkyl, or C₁-C₆ alkoxy-C₁-C₆alkyloxy, R₃ is C₁-C₆ alkyl, R₄ is C₁-C₆ alkyl, to form a compound of Formula-III,




Formula-III

b) converting cyano group of compound of Formula-III into amide group to give compound of Formula-IV



Formula-IV

c) reducing azide group of compound of Formula-IV to form the amine group and isolating the compound of Formula-Ia; and



Formula-Ia

d) optionally converting compound of Formula-Ia into pharmaceutically acceptable salts.


DETAILED DESCRIPTION OF THE INVENTION

[0011] The present invention relates to novel process for the preparation of renin inhibitors like Aliskiren or its pharmaceutically acceptable salts.

- 5 [0012] The present invention further relates to novel intermediates used in the preparation of Aliskiren or its pharmaceutically acceptable salts.


[0013] The main aspect of the present invention provides, novel process for the preparation of renin inhibitor of compound of Formula-Ia comprising the steps of:

- 10 a) reacting compound of Formula-II, with a cyano compound 3-Amino-2,2-dimethyl-propionitrile



Formula-II


wherein R_1 and R_2 are independently of one another H, C_1 - C_6 alkyl, C_1 - C_6 halogen alkyl, C_1 - C_6 alkoxy, C_1 - C_6 alkoxy- C_1 - C_6 alkyl, or C_1 - C_6 alkoxy- C_1 - C_6 alkyloxy, R_3 is C_1 - C_6 alkyl, R_4 is C_1 - C_6 alkyl, to form a compound of Formula-III,



Formula-III


15

- b) converting cyano group of compound of Formula-III into amide group to give compound of Formula-IV;




Formula-IV

c) reducing azide group of compound of Formula-IV to form the amine group and isolating the compound of Formula-Ia; and



d) optionally converting compound of Formula-Ia into pharmaceutically acceptable salts.

- 5 **[0014]** In one embodiment, the obtained renin inhibitor compound of Formula-Ia is Aliskiren of Formula-I, wherein R₁ is O(CH₂)₃OCH₃, R₂ is OCH₃, R₃ and R₄ are isopropyl groups.




- [0015]** In literature Aliskiren has been prepared by aminolysis of the lactone intermediate with an amine followed by the reduction to get the 5,4-amino alcohol moiety. The aminolysis of the lactone has been carried out with 3-amino-2,2-dimethylpropionamide. It has been disclosed in literature that this aminolysis reaction is best carried out in neat without a solvent using excess of 3-amino-2,2-dimethylpropionamide. It has been suggested that this aminolysis reaction could be only completed if the amide used 5mol equivalents with respect to lactone. Also it has been described that the aminolysis can be completed in reasonable time if the reaction is carried out at higher temperature about 90-100°C.
- 10 It is described in literature that this aminolysis reaction is a reversible reaction and the reaction equilibrium can be only shifted to right if more quantity of the amine is used. Therefore to have an industrially/commercially viable process for production of aliskiren its imperative to have a reaction condition where this aminolysis could be done in reasonable time at comparatively lower temperature along with a simple recovery process for the un reacted 3-amino-2,2-dimethylpropionamide. The 3-amino-2,2-dimethyl-propionitrile being a liquid at room temperature in contrast to the 3-amino-2,2-dimethylpropionamide which is a solid using 3-amino-2,2-dimethyl-propionitrile for the aminolysis reaction in neat condition give a uniform homogeneous reaction mass causing effective mixing of the two reactants and thus a better, faster reaction. Also 3-amino-2,2-dimethyl-propionitrile being a liquid having lower solubility in water compare to the 3-amino-2,2-dimethylpropionamide its recovery after reaction from the reaction system by acid base treatment is much easier and effective. There by
- 25 resulting almost quantitative recovery of unreacted/unused 3-amino-2,2-dimethyl-propionitrile. Further

the 3-amino-2,2-dimethyl-propionitrile having lower boiling point it is easy to purify by distillation either during its preparation/recovery.

[0016] Accordingly compound of Formula-III is prepared by the reaction of compound of Formula-II with 3-Amino-2,2-dimethyl-propionitrile optionally in the presence of a base. The base used in this step may be organic or inorganic base, preferably organic base such as Triethylamine, diisopropylethylamine, etc., more preferably Triethylamine.

[0017] In one more embodiment cyano group of compound of Formula-III is converted into amide group in the presence of a base and an oxidizing agent like hydrogen peroxide. The base used here may be organic or inorganic base, preferably inorganic base such as alkaline earth metal hydroxides, carbonates, bicarbonates etc., more preferably Sodium hydroxide.

[0018] The amide compound of Formula-IV is converted into Aliskiren of compound of Formula-I by reducing the compound of Formula-IV. The process comprises reducing the azide group of compound of Formula-IV in the presence of alcoholic solvents and isolating Aliskiren or its pharmaceutically acceptable salts.



[0019] In one embodiment, the reduction of compound of Formula-IV is carried out in the presence of Palladium catalyst.


[0020] In one more embodiment, alcoholic solvents used in the reduction of azide intermediate is selected from ethanol, methanol and isopropanol, preferably methanol and ethanol.

25


[0021] The prior art processes involves the use of tert-butyl methyl ether as a solvent in the reduction of azide intermediate. The yield obtained by this process is low.

[0022] In one more embodiment the lactone compound of Formula-II is prepared by the conventional prior art methods for example disclosed in US 7009078.

- 5 [0023] The compound of Formula-II is alternatively prepared by cyclisation and azidation of the compound of Formula-V. The process for the preparation of compound of Formula-II from compound of Formula-V is schematically shown below.



- 10 [0024] The compound of Formula-V, wherein R_1 , R_2 , R_3 and R_4 are defined above, R_6 is C_1 - C_6 alkyl, R_7 is C_1 - C_6 alkyl or C_1 - C_6 alkoxy, including the preferences, Y is Cl, Br or I, and Z is Cl, Br or I is prepared by condensing the compound of Formula-A with Compound of Formula-B in the presence of an alkali metal or alkaline earth metal, wherein the improvement comprises after completion of the reaction the formed compound of Formula-V is purified by fractional distillation.







- 15 wherein R_1 , R_2 , R_3 and R_4 are defined above, R_6 is C_1 - C_6 alkyl, R_7 is C_1 - C_6 alkyl or C_1 - C_6 alkoxy, including the preferences, Y is Cl, Br or I, and Z is Cl, Br or I.

- [0025] Prior art US 7132569 discloses that the compound of Formula-V is purified by using flash
20 chromatography, which is not suitable on commercial scale. Present invention provides purification of compound of formula V by using fractional distillation method.

- [0026] The condensation of compound of Formula-A and compound of Formula-B takes place in the presence of alkali or alkaline earth metals like magnesium. The coupling of Grignard reagents with
25 compound of formula B in an ether such as, for example, tetrahydrofuran, methyl tetrahydrofuran or dioxan as solvents in the presence of catalytic quantities of a soluble metal complex, for example an iron complex such as iron acetylacetonate, and in the presence of more than equimolar quantities of a solvent stabilizing the metal complex, for example N-methylpyrrolidone. It is expedient to carry out the

reaction so that initially a compound of formula-A is converted to a Grignard compound (for example with magnesium) and then adding a solution of a compound of formula-B, metal complex and N-methylpyrrolidone, or vice versa.


- 5 [0027] According to the present invention, fraction-I, which contains low boiling impurities are distilled out at bath/mass temperature of 90 °C to 150 °C, (vapour temperature 40 °C to 130 °C), preferably at a temperature of 110 °C to 130 °C, (vapour temperature 60 °C to 110 °C). Fraction-II, which contains starting material A2, Methyl impurity and hydroxyl impurities are distilled out at bath/mass temperature of 170 °C to 260 °C, (vapour temperature 120 °C to 180 °C), preferably at a temperature of 200 °C to 240 °C, (vapour temperature 140 °C to 160 °C) to yield the compound of Formula-V. The purity of the compound increases from 70 to above 90 % after distillation; preferably it is above 95%. This purity will enhance the purity of Aliskiren.

Hydroxy impurity	
Methyl impurity	
Impurity A1	
Starting material A2	

- 15 [0028] The compounds of Formula-A and Formula-B are prepared as per the conventional methods, for example the processes disclosed in US 5559111 and US 7009078.


[0029] Process for the preparation of Aliskiren as per the present invention, is summarized in the

scheme-I.



Scheme-I

[0030] In one more aspect, the present invention provides novel intermediate of compound of Formula-III



wherein R_1 and R_2 are independently of one another H, C_1 - C_6 alkyl, C_1 - C_6 halogen alkyl, C_1 - C_6 alkoxy, C_1 - C_6 alkoxy- C_1 - C_6 alkyl, or C_1 - C_6 alkoxy- C_1 - C_6 alkyloxy, R_3 is C_1 - C_6 alkyl, and R_4 is C_1 - C_6 alkyl.

[0031] In one embodiment, the compound of Formula-III is converted into Aliskiren or its pharmaceutically acceptable salts thereof.

[0032] The following examples are provided to illustrate the process of the present invention. They, are however, not intended to limiting the scope of the present invention in any way and several variants of these examples would be evident to person ordinarily skilled in the art.

5 Experimental procedure:

Example-1

Synthesis of 3-Amino-2,2-dimethyl-propionitrile:

[0033] A mixture of 3-amino-2,2-dimethylpropionamide (2.0 g) and thionyl chloride (3.0 g) in 15 ml ethylenedichloride was refluxed at 75-80° C for a period of 5 hrs. The reaction mixture was
10 concentrated to remove excess thionyl chloride and the residue was diluted with dichloromethane and washed with saturated sodium hydrogen carbonate solution. The dichloromethane solution was further washed with brine and concentrated to get 3-Amino-2,2-dimethyl-propionitrile as an oil.

Example-2

Synthesis of 3-Amino-2,2-dimethyl-propionitrile:

15 [0034] A mixture of 3-amino-2,2-dimethylpropionamide (10 g) and POCl₃(40 g) in 50ml toluene was maintained at 90-95° C for a period of 12-16 hrs. The reaction mixture was concentrated to remove excess POCl₃. The reaction mass was cooled to 10-15° C and diluted with water. pH of the reaction mass was adjusted 14 with 30% aq. Sodium hydroxide solution. The aqueous layer was extracted with dichloromethane (2x50 mL). Combined dichloromethane layer was washed with brine solution (20 mL)
20 and concentrated to get 3-Amino-2,2-dimethyl-propionitrile (7g) as an oil.

Example-3

Process for the preparation of compound of Formula-V (where R₁ = OCH₂OCH₂CH₃, R₂=OCH₃, R₃, R₄ = -CH(CH₃)₂, and R₆, R₇=Me).

[0035] A mixture of magnesium powder (15.5 g) and 2-methyltetrahydrofuran (175 ml) was heated to
25 60 °C and 1,2-dibromoethane (1 ml) was added over a period of 2 minutes. A solution of 2-{4-methoxy-3-(3-methoxypropoxyl)]-phenylmethyl-3-methyl-1-chlorobutane (50 g), 1,2-dibromoethane (5.6 ml) and 2-methyltetrahydrofuran (500 ml) was added dropwise over a period of 15 minutes at 60-65 °C. The reaction mixture was stirred under reflux and cooled to ambient temperature. There after was added to a solution of 5-chloro-2-isopropyl-n,n-dimethylpent-4-enamide-(2S,4E) (27.5 g), N-methylpyrrolidone (0.30 g) and iron (III) acetyl acetonate (1.2 g) in 2-methyltetrahydrofuran (300 ml).
30

The reaction mixture was agitated further 15 minutes at 10 °C and quenched with dilute hydrochloric acid. The reaction mixture was extracted with ethyl acetate and the organic phases washed consecutively with water and saturated aqueous sodium chloride solution. The combined organic phases were dried over sodium sulfate, filtered and concentrated. Product purified by fractional distillation (0.1-3 mbar) at 250°C. The unreacted starting materials along with the process byproducts are removed at 200°C under reduced pressure leaving behind pure product. (~57g, 80% yield).

Example-4

Process for the preparation of compound of Formula-V (where R₁= OCH₂OCH₂CH₃, R₂=OCH₃, R₃, R₄= -CH(CH₃)₂, and R₆, R₇=Me).

[0036] A mixture of Magnesium powder (15.5 g) and tetrahydrofuran (175 ml) was heated to reflux and 1,2-dibromoethane (1 ml) was added over a period of 2 minutes. A solution of 2-{4-methoxy-3-(3-methoxypropoxy)]-phenylmethyl-3-methyl-1-chlorobutane (50 g), 1,2-dibromoethane (5.6 ml) and Tetrahydrofuran (500 ml) was added dropwise over a period of 15 minutes at 60-65 °C. The reaction mixture was stirred under reflux and cooled to ambient temperature. There after was added to a solution of 5-chloro-2-isopropyl-n,n-dimethylpent-4-enamide-(2S,4E) (27.5 g), N-methylpyrrolidone (0.30 g) and iron (III) acetyl acetonate (1.2 g) in tetrahydrofuran (300 ml). The reaction mixture was agitated further 15 minutes at 10 °C and quenched with dilute hydrochloric acid. The reaction mixture was extracted with diisopropylether and the organic phases washed consecutively with water and saturated aqueous sodium chloride solution. The combined organic phases were dried over sodium sulfate, filtered and concentrated. Product purified by fractional distillation (0.1-3 mbar) at 250°C. The unreacted starting materials along with the process byproducts are removed at 200°C under reduced pressure leaving behind pure product. (~57g, 80% yield).

Example-5

Process for the preparation of compound of Formula-V (where R₁= OCH₂OCH₂CH₃, R₂=OCH₃, R₃, R₄= -CH(CH₃)₂, and R₆, R₇=Me).


[0037] A mixture of magnesium powder (8.4 g) and tetrahydrofuran (75 ml) was heated to 60-65°C and Iodine (100mg) was added. A solution of 2-{4-methoxy-3-(3-methoxypropoxy)]-phenylmethyl-3-methyl-1-chlorobutane (40 g), 1,2-dibromoethane (1.2g) and tetrahydrofuran (200 ml) was added dropwise over a period of 15-30 minutes at 60-65 °C. The reaction mixture was stirred under reflux and cooled to ambient temperature. There after was added a solution of 5-chloro-2-isopropyl-n,n-dimethylpent-4-enamide-(2S,4E) (25.4 g), N-methylpyrrolidone (0.36 g) and iron (III) acetyl acetonate (0.54 g) in tetrahydrofuran (300 ml) at 0°C. The reaction mixture was agitated further 15 minutes at 10 °C and quenched with dilute hydrochloric acid. The reaction mixture was extracted with

diisopropylether and the organic phases washed consecutively with water and saturated aqueous sodium chloride solution. The combined organic phases were dried over sodium sulfate, filtered and concentrated. Product purified by fractional distillation (0.1-3 mbar) at 250°C. The unreacted starting materials along with the process byproducts are removed at 200°C under reduced pressure leaving
5 behind pure product. (~46g, 80% yield).

Example-6

Preparation of Bromo lactone compound.

[0038]




[0039] Compound of Formula-V (15 gm), obtained from example-2 and THF (165 ml) was taken in a RB flask at 30°C. To this reaction mixture DM water (1.68 ml) was added and stirred. The reaction mass was cooled and to this ortho-phosphoric acid (2.3 ml) and N-bromo succinamide (6.6 gm) were
15 added lotwise alternatively in every 3 min gap and temperature was maintained at 5°C for 1-2 hrs. After completion of the reaction, reaction mass was quenched with Sodium hydrogen sulphite and reaction mass was extracted with isopropyl ether (225 ml). Organic layer was washed with 1N HCl (150 ml) followed by water. The organic layer was washed with saturated sodium bicarbonate solution and brine solution. Organic layer was dried with sodium sulphate and the solvent was distilled out completely
20 under vacuum. The obtained residue was crystallized in a mixture of 1:2 IPE/n-hexane. The compound was filtered and washed with pre cooled 1:2 IPE/n-hexane. The wet compound was dried to yield Bromo lactone compound.

Example-7

Process for the preparation of azide compound-X

25


[0040]



[0041] Toluene (150 ml) and the bromo lactone compound (4.28 gm) obtained from example-3 was taken in a flask and sodium azide (5.2 gm) was added. To this DM water (10 ml) and Aiquat-336 (1.0 gm) was added and the reaction mass was maintained at 75-80°C for 48 hrs. To this DM water (50 ml) was added. The layers were separated and reaction mass was extracted with toluene (100 ml). Organic layers were combined and washed with DM water (50 ml). Organic layer was dried with sodium sulphate and the solvent was distilled out completely under vacuum. The Obtained residue, was crystallized in a mixture of 1:2 IPE/n-hexane. The compound was filtered and washed with pre cooled 1:2 IPE/n-hexane. The wet compound was dried to yield azide compound-X.

Example-8

10 [0042] Synthesis of compound-Y:



[0043] A mixture of compound-X (12.0 g), 3-Amino-2,2-dimethyl-propionitrile (4.2 g), 45 mg 2-hydroxypyridine in 12 ml triethylamine was stirred for about 30 hours at 80-90°C. The progress of the reaction was monitored by HPLC analysis. After completion of the reaction it was concentrated to residue and the residue was dissolved in diisopropyl ether and stirred with aqueous NaOH to remove unreacted compound X. The layers were separated and the diisopropyl ether extract was concentrated to give residue (13.0g).

Example-9

Synthesis of compound-Y:


20 [0044] A mixture of compound-X (12.0 g), 3-Amino-2,2-dimethyl-propionitrile (4.2 g), 3.7g of 2-hydroxypyridine in 12 ml triethylamine was stirred for about 30 hours at 80-90°C. The progress of the reaction was monitored by HPLC analysis. After completion of the reaction it was concentrated to residue and the residue was dissolved in diisopropyl ether and stirred with aqueous NaOH to remove unreacted compound X. The layers were separated and the diisopropyl ether extract was concentrated to give residue (12.0g).

Example-10**Synthesis of compound-Y:**

[0045] A mixture of compound-X (12.0 g), 3-Amino-2,2-dimethyl-propionitrile (4.2 g), 3.7g 2-hydroxypyridine in 12ml triethylamine was stirred for about 36 hours at 60-65°C. The progress of the reaction was monitored by HPLC analysis. After completion of the reaction it was concentrated to residue and the residue was dissolved in diisopropyl ether and stirred with aqueous NaOH to remove unreacted compound X. The layers were separated and the diisopropyl ether extract was concentrated to give residue (12.5g).

Example-11**10 Synthesis of compound-Z:**

[0046]



[0047] To a solution of Compound-Y (13g, obtained in example 2) was dissolved in aqueous NaOH (5g dissolved in 45 ml of DM water), 35% Hydrogen peroxide (20 ml) was added at room temperature and stirred the at 30°- 40 °C for 2-4h. The progress of the reaction was monitored by HPLC analysis. After completion of the reaction the peroxides were destroyed by stirring with sodium bisulfite solution. Thereafter product was extracted in dichloromethane (3x75 ml). The dichloromethane extract was washed with brine and concentrated to obtain compound Z as a viscous liquid (12.3 g).

20 Example-12**Synthesis of Aliskiren hemifumarate:**

[0048] Compound-Z (12.3g, obtained in example 3) and of ethanolamine (1.3g) were dissolved in ethanol and hydrogenated at about 3Kg pressure in presence of Pd/C (600mg, 5% w/w) for 3-4h. The catalyst was filtered and the clear filtrate was treated with fumaric acid (1.23g). The solution was filtered through Celite pad to get a particle free solution which was further concentrated under reduced pressure below 40°C. Acetonitrile was added to the concentrate and distillation was continued to remove residual ethanol. To this residue a mixture of acetonitrile/ethanol (97:3) was added and the obtained solution was stirred overnight to crystallize the product. The product slurry was cooled,

filtered and washed with pre chilled acetonitrile. The product was dried under vacuum at 35°C to give the Aliskiren hemifumarate (9g).

Example-13

Synthesis of Aliskiren hemifumarate:

5 [0049] Compound-Z (6g) and ethanolamine (0.9g) were dissolved in methanol and hydrogenated at about 3Kg pressure in presence of Pd/C (600mg, 5% w/w) for 3-4h. The catalyst was filtered and the clear filtrate was treated with fumaric acid (600mg). The solution was filtered through Celite pad to get a particle free solution which was further concentrated under reduced pressure below 40°C. Acetonitrile was added to the concentrate and distillation was continued to remove residual methanol. To this
10 residue a mixture of acetonitrile/ethanol (97:3) was added and the obtained solution was stirred overnight to crystallize the product. The product slurry was cooled, filtered and washed with pre chilled acetonitrile. The product was dried under vacuum at 35°C to give the Aliskiren hemifumarate (4g).

Example-14

Process for the preparation of Aliskiren Hemifumarate from compound of Formula-IV (where

15 R₁= OCH₂OCH₂CH₃, R₂=OCH₃, R₃, R₄= -CH(CH₃)₂).

[0050] The azide compound of Formula-IV was hydrogenated for 4 hours in the presence of 10% Pd/C (1 g) and ethanolamine (1 g) in ethanol (100 ml) at ambient temperature and 3.0 Mbar pressure. The reaction mixture was filtered and the catalyst was washed with ethanol (25 ml). The obtained residue was dissolved in tert-butyl methyl ether and consequently washed with water and brine. The combined
20 organic phases were dried over anhydrous sodium sulfate and concentrated to give the residue. The residue was mixed with fumaric acid (0.5 g) dissolved in ethanol and filtered. The filtrate was concentrated by evaporation to a total weight of 7.0 grams and dissolved in acetonitrile (125 ml) at 35 °C. The resulting mixture was inoculated with 10mg of Aliskiren hemifumarate and agitated for 17 hours at ambient temperature. The suspension was cooled to 0 °C and filtered off by suction after 2
25 hours. The residue was washed with acetonitrile and then dried under vacuum at 35°C to yield Aliskiren hemifumarate as white crystals.

Example-15

Process for the preparation of Aliskiren Hemifumarate from compound of Formula-IV (where

R₁= OCH₂OCH₂CH₃, R₂=OCH₃, R₃, R₄= -CH(CH₃)₂).

[0051] The azide compound of Formula-IV was hydrogenated for 4 hours in the presence of 10% Pd/C (1 g) and ethanolamine (1 g) in methanol (100 ml) at ambient temperature and 3.0 Mbar pressure. The reaction mixture was filtered and the catalyst was washed with methanol (25 ml). The obtained residue was dissolved in tert-butyl methyl ether and consequently washed with water and brine. The combined
5 organic phases were dried over anhydrous sodium sulfate and concentrated to give the residue. The residue was mixed with fumaric acid (0.5 g) dissolved in ethanol and filtered. The filtrate was concentrated by evaporation to a total weight of 7.0 grams and dissolved in acetonitrile (125 ml) at 35 °C. The resulting mixture was inoculated with 10mg of Aliskiren hemifumarate and agitated for 17 hours at ambient temperature. The suspension was cooled to 0 °C and filtered off by suction after 2
10 hours. The residue was washed with acetonitrile and then dried under vacuum at 35°C to yield Aliskiren hemifumarate as white crystals.

15

20

25

30


Patentkrav

1. Fremgangsmåde til fremstilling af aliskiren eller farmaceutiske acceptable salte heraf, hvilken fremgangsmåde omfatter trinene

5


- a) omdannelse af cyano-gruppen i en forbindelse med formel-III til en amid-gruppe for at opnå en forbindelse med formel -IV;

10



15

Formel-III




20

Formel-IV

5 hvor R₁ og R₂ uafhængigt af hinanden er H, C₁-C₆ alkyl, C₁-C₆ halogenalkyl, C₁-C₆ alkoxy, C₁-C₆ alkoxy-C₁-C₆ alkyl eller C₁-C₆ alkoxy-C₁-C₆ alkyloxy, R₃ er C₁-C₆ alkyl og R₄ er C₁-C₆ alkyl,

b) reduktion af azid-gruppen i forbindelsen med formel-IV for at danne en amin-gruppe og isolering af forbindelsen med formel-Ia; og




Formel-Ia

c) eventuelt omdannelse af forbindelsen med formel-Ia til et farmaceutisk acceptabelt salt.

15

2. Fremgangsmåde ifølge krav 1, hvor forbindelsen med formel-III er fremstillet ved at omsætte en forbindelse med formel-II med 3-amino-2,2-dimethyl-propionitril



Formel-II

5 hvor R₁ og R₂ uafhængigt af hinanden er H, C₁-C₆ alkyl, C₁-C₆ halogenalkyl, C₁-C₆ alkoxy, C₁-C₆ alkoxy-C₁-C₆ alkyl eller C₁-C₆ alkoxy-C₁-C₆ alkyloxy, R₃ er C₁-C₆ alkyl og R₄ er C₁-C₆ alkyl.

3. Fremgangsmåde ifølge krav 1, hvor reduktionen af azid-gruppen i forbindelsen med formel-IV sker ved hjælp af Pd/C.

10 4. Fremgangsmåde ifølge krav 1, hvor reduktionen af azid-gruppen i forbindelsen med formel-IV sker i nærvær af et alkoholisk opløsningsmiddel.

15 5. Fremgangsmåde ifølge krav 4, hvor det alkoholiske opløsningsmiddel brugt i reduktion af azid-gruppen i forbindelsen med formel-IV vælges fra ethanol, methanol og isopropanol.

6. Fremgangsmåde ifølge krav 2, hvor forbindelsen med formel-V er fremstillet fra forbindelsen med formel-V.

20



Formel-V


hvor R_1 og R_2 uafhængigt af hinanden er H, C₁-C₆ alkyl, C₁-C₆ halogenalkyl, C₁-C₆ alkoxy, C₁-C₆ alkoxy-C₁-C₆ alkyl, eller C₁-C₆ alkoxy-C₁-C₆ alkyloxy, R_3 er C₁-C₆ alkyl, R_4 er C₁-C₆ alkyl, R_6 er C₁-C₆ alkyl og R_7 er C₁-C₆ alkyl eller C₁-C₆ alkoxy.

5

7. Fremgangsmåde ifølge krav 6, hvor forbindelsen med formel-V er oprenset ved fraktioneret destillation.

10

8. Forbindelse med formel-III



Formel-III

15

hvor R_1 og R_2 uafhængigt af hinanden er H, C₁-C₆ alkyl, C₁-C₆ halogenalkyl, C₁-C₆ alkoxy, C₁-C₆ alkoxy-

C₁-C₆ alkyl, eller C₁-C₆ alkoxy-C₁-C₆ alkyloxy, R_3 er C₁-C₆ alkyl og R_4 er C₁-C₆ alkyl.

20

9. Anvendelse af en forbindelse med formel-III i fremstilling af aliskiren eller farmaceutisk acceptable salte derfra.

25

10. Forbindelse med formel-A1.

